EVIDENCE FOR PROTECTIVE EFFECT OF AN INACTIVATED RHINOVIRUS VACCINE ADMINISTERED BY THE NASAL ROUTE

Abstract
Perkins, J. C (Lab. Infectious Diseases, NIAID, NIH, Bethesda, Md. 20014), D. N. Tucker, H. L S. Knopf, R. P. Wenzel, R. B. Homick, A. Z. Kapikian and R. M. Qianock. Evidence for protective effect of an inactivated rhinovirus vacdne administered by the nasal route. Amer. L Epid., 1969, 90: 319–326.—The antigenidty and protective effect of an inactivated rhinovirus type 13 vacdne administered intranasally (IN) were evaluated in adult male volunteers. After IN vacdnation, 14 of 17 vaccinees developed a fourfold or greater rise in nasal and/or serum antibody. A significant protective effect of the IN vacdne was seen when the men were challenged with 101.7–102.5 TCD50 of type 13 virus—11 of 13 seronegative controls became ill while only 4 of 12 vaccinees developed illness (p < 0.05).

This publication has 0 references indexed in Scilit: